Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?

Drug Resistance Updates

Volumn 16, Issue 3-5, 2013, Pages 68-72

  Britschgi, Adrian ^a   Radimerski, Thomas ^b   Bentires Alj, Mohamed ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ABX IL 8; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FEDRATINIB; INTERLEUKIN 8; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; K RAS PROTEIN; MOMELOTINIB; NAVARIXIN; NVP BSK 805; PACRITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; REPARIXIN; RUXOLITINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ASTHMA; BLADDER CANCER; BREAST CANCER; BREAST METASTASIS; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CANCER; CYTOKINE RELEASE; GENE MUTATION; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELOFIBROSIS; NONHUMAN; ONCOGENE K RAS; OPEN READING FRAME; OVERALL SURVIVAL; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; THROMBOCYTHEMIA; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOMODULATION; INTERLEUKIN-8; JANUS KINASE 2; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84890115298     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2013.10.001     Document Type: Review

References (37)

1. N. Aceto, S. Duss, G. Macdonald, D.S. Meyer, T.C. Roloff, N.E. Hynes, and M. Bentires-Alj Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion Breast Cancer Res 14 2012 R131
2. A. Britschgi, R. Andraos, H. Brinkhaus, I. Klebba, V. Romanet, U. Muller, M. Murakami, T. Radimerski, and M. Bentires-Alj JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer Cancer Cell 22 2012 796 811
3. A. Chakrabarty, N.E. Bhola, C. Sutton, R. Ghosh, M.G. Kuba, B. Dave, J.C. Chang, and C.L. Arteaga Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors Cancer Res 73 2012 1190 1200
4. S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik-Outmezguine, O. Grbovic-Huezo, V. Serra, P.K. Majumder, J. Baselga, and N. Rosen AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity Cancer Cell 19 2011 58 71
5. C. Chavey, F. Bibeau, S. Gourgou-Bourgade, S. Burlinchon, F. Boissiere, D. Laune, S. Roques, and G. Lazennec Oestrogen receptor negative breast cancers exhibit high cytokine content Breast Cancer Res 9 2007 R15
6. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
7. F. Di Nicolantonio, S. Arena, J. Tabernero, S. Grosso, F. Molinari, T. Macarulla, M. Russo, C. Cancelliere, D. Zecchin, L. Mazzucchelli, T. Sasazuki, S. Shirasawa, M. Geuna, M. Frattini, J. Baselga, x.E.M. Gallicchio, S. Biffo, and A. Bardelli Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus J Clin Invest 120 2010 2858 2866
8. M. Elkabets, S. Vora, D. Juric, N. Morse, M. Mino-Kenudson, T. Muranen, J. Tao, A.B. Campos, J. Rodon, Y.H. Ibrahim, V. Serra, V. Rodrik-Outmezguine, S. Hazra, S. Singh, P. Kim, C. Quadt, M. Liu, A. Huang, N. Rosen, J.A. Engelman, M. Scaltriti, and J. Baselga mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer Sci Transl Med 5 2013 196ra199
9. J.A. Engelman, L. Chen, X. Tan, K. Crosby, A.R. Guimaraes, R. Upadhyay, M. Maira, K. McNamara, S.A. Perera, Y. Song, L.R. Chirieac, R. Kaur, A. Lightbown, J. Simendinger, T. Li, R.F. Padera, C. Garcia-Echeverria, R. Weissleder, U. Mahmood, L.C. Cantley, and K.K. Wong Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 2008 1351 1356
10. J.A. Engelman, J. Luo, and L.C. Cantley The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 2006 606 619
11. A.C. Faber, D. Li, Y. Song, M.C. Liang, B.Y. Yeap, R.T. Bronson, E. Lifshits, Z. Chen, S.M. Maira, C. Garcia-Echeverria, K.K. Wong, and J.A. Engelman Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition Proc Natl Acad Sci U S A 106 2009 19503 19508
12. C. Ginestier, S. Liu, M.E. Diebel, H. Korkaya, M. Luo, M. Brown, J. Wicinski, O. Cabaud, E. Charafe-Jauffret, D. Birnbaum, J.L. Guan, G. Dontu, and M.S. Wicha CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts J Clin Invest 120 2010 485 497
13. C. Harrison, J.J. Kiladjian, H.K. Al-Ali, H. Gisslinger, R. Waltzman, V. Stalbovskaya, M. McQuitty, D.S. Hunter, R. Levy, L. Knoops, F. Cervantes, A.M. Vannucchi, T. Barbui, and G. Barosi JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
14. T. Haruta, T. Uno, J. Kawahara, A. Takano, K. Egawa, P.M. Sharma, J.M. Olefsky, and M. Kobayashi A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1 Mol Endocrinol 14 2000 783 794
15. M. Hedvat, D. Huszar, A. Herrmann, J.M. Gozgit, A. Schroeder, A. Sheehy, R. Buettner, D. Proia, C.M. Kowolik, H. Xin, B. Armstrong, G. Bebernitz, S. Weng, L. Wang, M. Ye, K. McEachern, H. Chen, D. Morosini, K. Bell, M. Alimzhanov, S. Ioannidis, P. McCoon, Z.A. Cao, H. Yu, R. Jove, and M. Zinda The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors Cancer Cell 16 2009 487 497
16. S. Huang, L. Mills, B. Mian, C. Tellez, M. McCarty, X.D. Yang, J.M. Gudas, and M. Bar-Eli Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma Am J Pathol 161 2002 125 134
17. N. Ilic, T. Utermark, H.R. Widlund, and T.M. Roberts PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis Proc Natl Acad Sci U S A 108 2011 E699 E708
18. S. Koren, and M. Bentires-Alj Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors FEBS J 280 2013 2758 2765
19. H. Korkaya, G.I. Kim, A. Davis, F. Malik, N.L. Henry, S. Ithimakin, A.A. Quraishi, N. Tawakkol, R. D'Angelo, A.K. Paulson, S. Chung, T. Luther, H.J. Paholak, S. Liu, K.A. Hassan, Q. Zen, S.G. Clouthier, and M.S. Wicha Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population Mol Cell 47 2012 570 584
20. P. Liu, H. Cheng, S. Santiago, M. Raeder, F. Zhang, A. Isabella, J. Yang, D.J. Semaan, C. Chen, E.A. Fox, N.S. Gray, J. Monahan, R. Schlegel, R. Beroukhim, G.B. Mills, and J.J. Zhao Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms Nat Med 17 2011 1116 1120
21. S.M. Maira, S. Pecchi, A. Huang, M. Burger, M. Knapp, D. Sterker, C. Schnell, D. Guthy, T. Nagel, M. Wiesmann, S. Brachmann, C. Fritsch, M. Dorsch, P. Chene, K. Shoemaker, A. De Pover, D. Menezes, G. Martiny-Baron, D. Fabbro, C.J. Wilson, R. Schlegel, F. Hofmann, C. Garcia-Echeverria, W.R. Sellers, and C.F. Voliva Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor Mol Cancer Ther 11 2012 317 328
22. L.L.C. Marotta, V. Almendro, A. Marusyk, M. Shipitsin, J. Schemme, S.R. Walker, N. Bloushtain-Qimron, J.J. Kim, S.A. Choudhury, R. Maruyama, Z. Wu, M. GÃnen, L.A. Mulvey, M.O. Bessarabova, S.J. Huh, S.J. Silver, S.Y. Kim, S.Y. Park, H.E. Lee, K.S. Anderson, A.L. Richardson, T. Nikolskaya, Y. Nikolsky, X.S. Liu, D.E. Root, W.C. Hahn, D.A. Frank, and K. Polyak The JAK2/STAT3 signaling pathway is required for growth of CD44+ CD24- stem cell-like breast cancer cells in human tumors J Clin Invest 121 2011 2723 2735
23. B.M. Mian, C.P. Dinney, C.E. Bermejo, P. Sweeney, C. Tellez, X.D. Yang, J.M. Gudas, D.J. McConkey, and M. Bar-Eli Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB Clin Cancer Res 9 2003 3167 3175
24. M.K. Muellner, I.Z. Uras, B.V. Gapp, C. Kerzendorfer, M. Smida, H. Lechtermann, N. Craig-Mueller, J. Colinge, G. Duernberger, and S.M. Nijman A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer Nat Chem Biol 7 2011 787 793
25. T. Muranen, L.M. Selfors, D.T. Worster, M.P. Iwanicki, L. Song, F.C. Morales, S. Gao, G.B. Mills, and J.S. Brugge Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells Cancer Cell 21 2012 227 239
26. Y. Ning, M.J. Labonte, W. Zhang, P.O. Bohanes, A. Gerger, D. Yang, L. Benhaim, D. Paez, D.O. Rosenberg, K.C. Nagulapalli Venkata, S.G. Louie, N.A. Petasis, R.D. Ladner, and H.J. Lenz The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models Mol Cancer Ther 11 2012 1353 1364
27. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, D. Smith, H. Lane, F. Hofmann, D.J. Hicklin, D.L. Ludwig, J. Baselga, and N. Rosen mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508
28. T. Radimerski, J. Montagne, M. Hemmings-Mieszczak, and G. Thomas Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling Genes Dev 16 2002 2627 2632
29. V. Serra, P.J. Eichhorn, C. Garcia-Garcia, Y.H. Ibrahim, L. Prudkin, G. Sanchez, O. Rodriguez, P. Anton, J.L. Parra, S. Marlow, M. Scaltriti, J. Perez-Garcia, A. Prat, J. Arribas, W.C. Hahn, S.Y. Kim, and J. Baselga RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer J Clin Invest 123 2013 2551 2563
30. V. Serra, M. Scaltriti, L. Prudkin, P.J. Eichhorn, Y.H. Ibrahim, S. Chandarlapaty, B. Markman, O. Rodriguez, M. Guzman, S. Rodriguez, M. Gili, M. Russillo, J.L. Parra, S. Singh, J. Arribas, N. Rosen, and J. Baselga PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer Oncogene 30 2011 2547 2557
31. J.K. Singh, G. Farnie, N.J. Bundred, B.M. Simoes, A. Shergill, G. Landberg, S.J. Howell, and R.B. Clarke Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms Clin Cancer Res 19 2012 643 656
32. S. Singh, A. Sadanandam, K.C. Nannuru, M.L. Varney, R. Mayer-Ezell, R. Bond, and R.K. Singh Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis Clin Cancer Res 15 2009 2380 2386
33. S.Y. Sun, L.M. Rosenberg, X. Wang, Z. Zhou, P. Yue, H. Fu, and F.R. Khuri Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition Cancer Res 65 2005 7052 7058
34. M.L. Varney, S. Singh, A. Li, R. Mayer-Ezell, R. Bond, and R.K. Singh Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases Cancer Lett 300 2011 180 188
35. S. Verstovsek, R.A. Mesa, J. Gotlib, R.S. Levy, V. Gupta, J.F. DiPersio, J.V. Catalano, M. Deininger, C. Miller, R.T. Silver, M. Talpaz, E.F. Winton, J.H. Harvey Jr., M.O. Arcasoy, E. Hexner, R.M. Lyons, R. Paquette, A. Raza, K. Vaddi, S. Erickson-Viitanen, I.L. Koumenis, W. Sun, V. Sandor, and H.M. Kantarjian A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 2012 799 807
36. D.J. Waugh, and C. Wilson The interleukin-8 pathway in cancer Clin Cancer Res 14 2008 6735 6741
37. H. Xin, A. Herrmann, K. Reckamp, W. Zhang, S. Pal, M. Hedvat, C. Zhang, W. Liang, A. Scuto, S. Weng, D. Morosini, Z.A. Cao, M. Zinda, R. Figlin, D. Huszar, R. Jove, and H. Yu Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480 Cancer Res 71 2011 6601 6610